Why this rocketing ASX 200 tech stock can fly even higher

A leading broker thinks this high-flying tech stock is a top buy right now.

| More on:
Man with rocket wings which have flames coming out of them.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

One of the best performers on the Australian share market over the past 12 months has been Pro Medicus Limited (ASX: PME).

Over the period, the ASX 200 tech stock has rocketed approximately 115%.

But if you thought the gains were over, think again!

Why this rocketing ASX 200 tech stock can keep rising

According to a note out of Goldman Sachs, its analysts believe that Pro Medicus shares can keep rising from current levels.

This is thanks to its market leadership position and competitive advantage over peers. Goldman explains:

PME continues to demonstrate strong momentum within the business, acquiring customers across a broad range of markets and specialties. Despite a material step-up in the frequency and value of recent contract wins, we believe the pipeline remains healthy with little sign of competition being close to matching the Visage solution. PME's share of the US market remains low at 7%, which highlights the opportunity ahead, notwithstanding upside prospects from the core TAM, adjacencies (cardiology & AI) and potential new markets.

Four reasons to buy

Goldman also highlights four reasons why it thinks the future is bright for this ASX 200 tech stock.

The first relates to its market share opportunity, which it believes can grow materially from 7% today. It said:

Long-term US market share >25%: Looking at US MedTech, we find there is significant opportunity to capture share (even in established markets) with particular segments dominated by one to two players.

Goldman likes the strong return on investment (ROI) that Pro Medicus' Visage offering generates. It explains:

Strong ROI generated through Visage: Our analysis shows a clinic could return >16x the cost of Visage assuming a +25% increase in scan volumes, which should justify the incremental cost paid to PME.

The broker also highlights that the company has opportunities to grow its core total addressable market (TAM) materially. It explains:

Growth in the core TAM: We estimate the US Department of Defence opportunity could present an additional +50mn scans p.a., with Europe being a key longer-term growth opportunity as regulatory obstacles clear.

Finally, Goldman sees artificial intelligence (AI) and cardiology adoption as key drivers of growth. It said:

Adjacencies approaching broader adoption: PME looks well positioned to take share in cardiology and AI, being uniquely partnered with medical KOLs in settings that are generally well-funded and willing to adopt new technology, helping drive a network effect through the industry

Time to buy

In light of this, the broker has boosted its earnings estimates and valuation accordingly.

And while it acknowledges that the ASX 200 tech stock is not cheap, it believes this is justified by its " revenue/margin outlook, unique cloud offering, and significant long-term opportunity."

Goldman has reiterated its buy rating on Pro Medicus' shares and lifted its price target by 30% to $193.00. This implies potential upside of 12% for investors from current levels.

Motley Fool contributor James Mickleboro has positions in Pro Medicus. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group and Pro Medicus. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Technology Shares

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Technology Shares

Here are 2 exciting ASX shares rated as buys

These shares are highly rated by brokers. Let's find out why.

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
Technology Shares

Is this the decade of the data centre? One ASX 200 stock that could benefit

Let's see why one leading broker thinks this stock could be destined for big things.

Read more »

A human-like robot checks out market performance on a laptop, indicating the rise of AI shares.
Technology Shares

3 top performing ASX AI shares for your watchlist

Have you positioned your portfolio to capitalise on the next tech revolution?

Read more »

Two IT professionals walk along a wall of mainframes in a data centre discussing various things
AI Stocks

3 reasons to buy NextDC shares today

A leading expert forecasts more growth to come for NextDC's rebounding shares.

Read more »

A share market analyst looks at his computer screen in front of him showing ASX share price movements
Technology Shares

Why this $3.9 billion acquisition makes Xero shares a buy today

A leading expert forecasts that Xero’s $3.9 billion investment is about to pay off.

Read more »

Three young people in business attire sit around a desk and discuss.
Small Cap Shares

Tiny tech: 3 ASX small-cap shares with new ratings

Toby Grimm of Baker Young and Peter Day of Sequoia Wealth Management share their new ratings.

Read more »

Smiling young parents with their daughter dream of success.
Technology Shares

Could Life360 shares rise to $37.50?

Bell Potter has given its verdict on this tech stock.

Read more »

Man smiling at a laptop because of a rising share price.
Technology Shares

Investors should put these 2 top ASX tech shares on the watchlist

Looking for growth? These two stocks are delivering.

Read more »